Drugs modulating the L-arginine:NO:cGMP pathway – current use in therapy

1. Akmal A.H., Hasan M.: Role of nitric oxide in management of acute respiratory distress syndrome. Ann. Thorac. Med., 3, 100-103, 2008.10.4103/1817-1737.41914270044419561888Search in Google Scholar

2. Amoruso A. et al.: Characterization of the anti-inflammatory properties of NCX 429, a dual-acting compound releasing nitric oxide and naproxen. Life Sci. 126, 28-36, 2015.10.1016/j.lfs.2015.01.02525711428Search in Google Scholar

3. Atkinson T.J. et al. What’s new in NSAID pharmacotherapy: oral agents to injectables. Pain Med. 1,S11-7, 2013.10.1111/pme.1227824373105Search in Google Scholar

4. Barnett C.F., Machado R.F.: Sildenafil in the treatment of pulmonary hypertension. Vasc. Health Risk. Manag., 2, 411-422, 2006.10.2147/vhrm.2006.2.4.411199402017323595Search in Google Scholar

5. Boden W.E. et al.: Role of short-acting nitroglycerin in the management of ischemic heart disease. Drug. Des. Devel. Ther., 9, 4793-4805, 2015.10.2147/DDDT.S79116454872226316714Search in Google Scholar

6. Bruckdorfer R.: The basics about nitric oxide. Mol. Aspects Med., 26, 3-31, 2005.10.1016/j.mam.2004.09.00215722113Search in Google Scholar

7. Buchwalow I. et al.: L-arginine-NO-cGMP signalling pathway in pancreatitis. Sci. Rep., 3, 1899, 2013.10.1038/srep01899366489723712581Search in Google Scholar

8. Butler A.R., Feelish M.: Therapeutic uses of inorganic nitrite and nitrate: from the past to the future. Circulation, 117, 2151-2159, 2008.10.1161/CIRCULATIONAHA.107.75381418427145Search in Google Scholar

9. Cannon R.O.: Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clin. Chem., 44, 1809-1819, 1998.10.1093/clinchem/44.8.1809Search in Google Scholar

10. Chen Y. et al.: Functional interplay between angiotensin II and nitric oxide: cyclic GMP as a key mediator. Arterioscl. Throm. Vas., 23, 26-36, 2003.10.1161/01.ATV.0000046231.17365.9D12524221Search in Google Scholar

11. DiBlasi R.M., Myers T.R., Hess D.R.: Evidence-based clinical practice guideline: inhaled nitric oxide for neonates with acute hypoxic respiratory failure. Respir. Care., 55, 1717-1745, 2010.Search in Google Scholar

12. DiNicolantonio J.J. et al.: β-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature. Open Heart, 2, 2015.10.1136/openhrt-2014-000230Search in Google Scholar

13. Evans J.D., Hill S.R: A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil. Patient. Prefer. Adherence, 9, 1159-1164, 2015.10.2147/PPA.S56002Search in Google Scholar

14. Fongemie J., Felix-Getzik E.: A Review of Nebivolol Pharmacology and Clinical Evidence. Drugs, 75, 1349-1371, 2015.10.1007/s40265-015-0435-5Search in Google Scholar

15. Forstermann U., Sessa W.C.: Nitric oxide synthases: regulation and function. Eur. Heart J., 33, 829-837, 2012.10.1093/eurheartj/ehr304Search in Google Scholar

16. Garry P. S. et al.: The role of the nitric oxide pathway in brain injury and its treatment - From bench to bedside. Exp. Neurol., 263, 235-243, 2015.10.1016/j.expneurol.2014.10.017Search in Google Scholar

17. Guix F. X. et al.: The physiology and pathophysiology of nitric oxide in the brain. Prog. Neurobiol., 76, 126-152, 2005.10.1016/j.pneurobio.2005.06.001Search in Google Scholar

18. Hakky T.S., Jain L.: Current use of phosphodiesterase inhibitors in urology, Turk. J. Urol., 41, 88-92, 2015.10.5152/tud.2015.46354Search in Google Scholar

19. Hambrecht R. et al.: Correction of endothelial dysfunction in chronic heart failure: additional effects of exercise training and oral L-arginine supplementation. J. Am. Coll. Cardiol., 35, 706-713, 2000.10.1016/S0735-1097(99)00602-6Search in Google Scholar

20. Herchuelz A. et al.: Clinical pharmacokinetics of once - daily molsidomine: From immediate - release to prolonged - release once - daily formulations. Am. J. Drug Delivery., 2, 131-141, 2004.10.2165/00137696-200402020-00005Search in Google Scholar

21. Hiremath J.G. et al.: Pharmaceutical aspects of nicorandil. Int. J. Pharm. Pharm. Sci., 2, 24-29, 2010.Search in Google Scholar

22. Horinaka S. et al.: Nicorandil protects against lethal ischemic ventricular arrhythmias and up-regulates endothelial nitric oxide synthase expression and sulfonylurea receptor 2 mRNA in conscious rats with acute myocardial infarction. Cardiovasc. Drugs Ther., 18, 13-22, 2004.10.1023/B:CARD.0000025751.82774.a9Search in Google Scholar

23. Hottinger D.G. et al.: Sodium nitroprusside in 2014: A clinical concepts review. J. Anaesthesiol. Clin. Pharmacol., 30, 462-471, 2014.10.4103/0970-9185.142799423477925425768Search in Google Scholar

24. Ignarro L.J., Napoli C., Loscalzo J.: Nitric Oxide Donors and Cardiovascular Agents Modulating the Bioactivity of Nitric Oxide. Circ. Res., 90, 21-28, 2002.10.1161/hh0102.10233011786514Search in Google Scholar

25. INOMAXR website [online]. [access: November 13, 2015]. Available at: < http://inomax.com/>.Search in Google Scholar

26. Kannam J., Gersh B.J.: Nitrates in the management of stable angina pectoris [online]. [access: November 13, 2015]. Available at: <http://www.uptodate.com/contents/nitrates-in-the-management -of-stable-angina-pectoris>.Search in Google Scholar

27. Kinoshita M., Sakai K.: Pharmacology and therapeutic effects of nicorandil. Cardiovasc. Drugs Ther., 4, 1075-1088, 1990.10.1007/BF018565032150592Search in Google Scholar

28. Kirkeboen K.A., Strand O.A.: Nitric oxide - an important mediator in sepsis? Tidsskr. Nor. Laegeforen., 119, 4061-4065, 1999.Search in Google Scholar

29. Kopkan L., Cervenka L.: Renal interactions of renin-angiotensin system, nitric oxide and superoxide anion: implications in the pathophysiology of salt-sensitivity and hypertension. Physiol. Res., 58, S55-S67, 2009.10.33549/physiolres.93191720131937Search in Google Scholar

30. Kuhl S.J, Rosen H.: Nitric oxide and septic shock. From bench to bedside. West. J. Med., 168, 176-181, 1998.Search in Google Scholar

31. Lakshminrusimha S.: The Pulmonary Circulation in Neonatal Respiratory Failure. Clin. Perinatol,. 39, 655-683, 2012.10.1016/j.clp.2012.06.006359862922954275Search in Google Scholar

32. Lerman A. et al.: Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation, 97, 2123-2128, 1998.10.1161/01.CIR.97.21.2123Search in Google Scholar

33. Ma F.X., Han Z.C.: Statins, nitric oxide and neovascularization, Cardiovasc. Drug Rev., 23, 281-292, 2005.10.1111/j.1527-3466.2005.tb00173.x16614729Search in Google Scholar

34. Maffei A., Lembo G.: Nitric oxide mechanisms of nebivolol. Ther. Adv. Cardiovasc. Dis., 3, 317-327, 2009.10.1177/175394470910449619443516Search in Google Scholar

35. Moncada S., Higgs E.A: The discovery of nitric oxide and its role in vascular biology. Br. J. Pharmacol., 147, S193-S201, 2006.10.1038/sj.bjp.0706458176073116402104Search in Google Scholar

36. Munzel T., Gori T.: Nebivolol: the somewhat-different betaadrenergic receptor blocker. J. Am. Coll. Cardiol., 54, 1491-1499, 2009.10.1016/j.jacc.2009.05.06619815121Search in Google Scholar

37. Munzel T.: Recent findings on nitrates: their action, bioactivation and development of tolerance. Dtsch. Med. Wochenschr., 133, 2277-2282, 2008.10.1055/s-0028-109127218946854Search in Google Scholar

38. Nichols S.P.et al.: Local delivery of nitric oxide: targeted delivery of therapeutics to bone and connective tissues. Adv. Drug Deliv. Rev. 64, 1177-1188, 2012.10.1016/j.addr.2012.03.002338391622433782Search in Google Scholar

39. Nossaman V.E. et al.: Nitrates and Nitrites in the Treatment of Ischemic Cardiac Disease. Cardiol. Rev., 18, 190-197, 2011.10.1097/CRD.0b013e3181c8e14a288501420539102Search in Google Scholar

40. Orzelska J., Talarek S.: The current approach to the central effects of sildenafil - role of nitric oxide: cGMP pathway. Ann. UMCS Lublin, Sectio DDD, 21, 139-147, 2008.10.2478/v10080-008-0021-1Search in Google Scholar

41. Pacurari M. et al.: The renin-angiotensin-aldosterone system in vascular inflammation and remodeling. Int. J. Inflam, Article ID 689360, doi: 10.1155/2014/689360, 2014.10.1155/2014/689360399786124804145Search in Google Scholar

42. Parker J.D., Gori T.: Tolerance to the organic nitrates: new ideas, new mechanisms, continued mystery. Circulation, 104, 2263-2265, 2001.10.1161/circ.104.19.2263Search in Google Scholar

43. Reden J.: Molsidomine. Blood Vessels, 27, 282-294, 1990.10.1159/0001588202242448Search in Google Scholar

44. Rossaint R. et al.: Inhaled Nitric Oxide for the Adult Respiratory Distress Syndrome. N. Engl. J. Med., 328, 399-405, 1993.10.1056/NEJM1993021132806058357359Search in Google Scholar

45. Schirmer S.H. et al.: Nitric oxide-donating statins: a new concept to boost the lipid-independent effects. Cardiovasc. Res., 94, 395-397, 2012.10.1093/cvr/cvs14822499774Search in Google Scholar

46. Scholtholt J. (1985). Molsidomine. In: Clinical Pharmacology of Anti-anginal Drugs. Abshagen U. (editors). Springer - Verlag Berlin Heidelberg; p. 365-377.Search in Google Scholar

47. Stolbach A., Chanmugam A.: Antihypertensive agents, 2015 [online]. [access: November 13, 2015]. Available at: <http://r.wildcatem. com/wp-content/uploads/2014/11/190_Antihypertensive-Agents_Tintinalli.pdf>Search in Google Scholar

48. The Official Website of Nobel Prize [online]. [access: November 13, 2015]. Available at: http://www.nobelprize.org/nobel_prizes/medicine/laureates/1998/illpres/Search in Google Scholar

49. Wimalawansa J.: Nitric oxide: new evidence for novel therapeutic indications. Expert. Opin. Pharmacother., 9, 1935-1954, 2008.10.1517/14656566.9.11.193518627331Search in Google Scholar

50. Yaseen H., Darwich M., Hamdy H.: Is Sildenafil an Effective Therapy in the Management of Persistent Pulmonary Hypertension? J. Clin. Neonatol., 1, 171-175, 2012.10.4103/2249-4847.105958376204324027721Search in Google Scholar

51. Zhou L., Zhu D.Y.: Neuronal Nitric oxide synthase: structure, subcellural localization, regulation and clinical implications. Nitric Oxide, 20, 223-230, 2009.10.1016/j.niox.2009.03.00119298861Search in Google Scholar